Katrine Bosley is the Chief Executive Officer of Editas Medicine (NASDAQ: EDIT).
Prior to joining Editas, Katrine was an Entrepreneur-in-Residence at The Broad Institute, a biomedical and genomic research center, and before that, she was the CEO of Avila Therapeutics (acquired by Celgene). Katrine was also VP, Business Development at Adnexus Therapeutics and then VP, Strategic Operations after Adnexus' acquisition by Bristol-Myers Squibb. Earlier, Katrine held several positions at Biogen in business development, commercial operations, and portfolio strategy and was part of the healthcare team at the venture firm Highland Capital Partners. She is a graduate of Cornell University.
In addition to her role at Editas, Katrine currently serves as Chairman of the Board of Genocea Biosciences (NASDAQ: GNCA) and is a member of the Board of Directors of Galapagos NV (EURONEXT and NASDAQ: GLPG), of BIO – the Biotechnology Innovation Organization, and of Massachusetts Eye and Ear.